UNASSIGNED: Patients with liver tumors proximal to the HBDs (≤5 mm) who underwent MWA at our hospital between June 2020 and April 2023 were retrospectively analyzed. The strategy of US-MR fusion imaging combined with PTCD-ICSP was used to assist the MWA procedures. The technical success, technique efficacy, local tumor progression, intrahepatic distant recurrence and complications were recorded and analyzed.
UNASSIGNED: In total, 12 patients with 12 liver tumors were retrospectively enrolled in this study. US-MR fusion imaging was utilized in all patients, and PTCD-ICSP assistance was successfully used for 4 nodules abutting HBDs (0 mm). The rates of technical success, technique efficacy, local tumor progression and intrahepatic distant recurrence were 91.7%, 83.3%, 0% and 8.3%, respectively. The major complication of biliary infection occurred in only one patient who had previously undergone left hemihepatectomy and bile-intestinal anastomosis.
UNASSIGNED: MWA for liver tumors proximal to HBDs assisted by US-MR fusion imaging combined with PTCD-ICSP was feasible and safe. This strategy made MWA of liver tumors abutting HBDs possible.
■在2020年6月至2023年4月期间在我们医院接受MWA的HBDs(≤5mm)近端肝肿瘤患者进行回顾性分析。US-MR融合成像结合PTCD-ICSP的策略用于辅助MWA程序。技术上的成功,技术功效,局部肿瘤进展,记录并分析肝内远处复发和并发症。
■总共,本研究回顾性纳入了12例肝脏肿瘤患者。所有患者均采用US-MR融合成像,PTCD-ICSP辅助已成功用于4个邻接HBD(0mm)的结节。技术成功率,技术功效,局部肿瘤进展和肝内远处复发率为91.7%,83.3%,0%和8.3%,分别。胆道感染的主要并发症仅发生在一名先前接受左半肝切除术和胆肠吻合术的患者中。
■MWA在US-MR融合成像联合PTCD-ICSP辅助下治疗HBD近端肝肿瘤是可行且安全的。这种策略使邻接HBDs的肝肿瘤的MWA成为可能。